HNSPF (Hansoh Pharmaceutical Group Co) Other Current Payables: $120 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSPF Hansoh Pharmaceutical Group Co Ltd HNSPF
92 GF Score
Price $3.83
GF Value $3.12
Valuation Fairly Valued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Other Current Payables?

Hansoh Pharmaceutical Group Co HNSPF 92 Other Current Payables is $120 Mil as of Dec. 2025. GuruFocus rates HNSPF with a GF Score™ of 92/100 and a GF Value™ of $3.12 (Fairly Valued).

Hansoh Pharmaceutical Group Co's Other Current Payables for the quarter that ended in Dec. 2025 was $120 Mil.

Hansoh Pharmaceutical Group Co's quarterly Other Current Payables increased from Dec. 2024 ($97 Mil) to Jun. 2025 ($201 Mil) but then declined from Jun. 2025 ($201 Mil) to Dec. 2025 ($120 Mil).

Hansoh Pharmaceutical Group Co's annual Other Current Payables increased from Dec. 2023 ($96 Mil) to Dec. 2024 ($97 Mil) and increased from Dec. 2024 ($97 Mil) to Dec. 2025 ($120 Mil).

Hansoh Pharmaceutical Group Co Other Current Payables Related Terms

Hansoh Pharmaceutical Group Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Other Current Payables Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 121.07 87.26 96.30 96.59 119.60

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.30 193.44 96.59 201.49 119.60
HNSPF
92GF Score
Hansoh Pharmaceutical Group Co Ltd HNSPF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $120 Mil mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Other Current Payables of $120 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hansoh Pharmaceutical Group Co and its competitors.
Is Hansoh Pharmaceutical Group Co's Other Current Payables too high?
Hansoh Pharmaceutical Group Co's current Other Current Payables is $120 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Other Current Payables compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Other Current Payables of $120 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Other Current Payables is $120 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.12, compared to a current price of $3.83 — trading 22.6% above its estimated fair value. The current Other Current Payables is $120 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Other Current Payables is $120 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of $3.83 is trading 22.6% above its estimated GF Value™ of $3.12. GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for HNSPF:

  • Other Current Payables: $120 Mil
  • GF Value™: $3.12 vs. price of $3.83 (22.6% above fair value)
  • GF Score™: 92/100

No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
92GF Score

Get the complete analysis for HNSPF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price
$3.12
GF Value